Score PASI (Zone atteinte et sévérité du psoriasis) 

Le score PASI : Le PASI (Psoriasis Area Severity Index) est un score clinique permettant d’évaluer quantitativement la sévérité du psoriasis en fonction de l’intensité des signes objectifs du psoriasis et de la surface cutanée.

L’indice PASI combine l’évaluation de quatre parties du corps :

  • La tête
  • Les membres supérieurs
  • Le tronc
  • Les membres inférieurs.

Dans chaque partie du corps, la sévérité des lésions (érythème, épaisseur/induration et desquamation) est évaluée sur une échelle en cinq points: 

Evaluation du score PASI


Score DLQI

Le score DLQI : Le DLQI est un index de qualité de vie qui quantifie:

  • les démangeaisons
  • la douleur
  • le sentiment de gêne/embarras
  • les problèmes liés au traitement
  • les répercussions de la maladie cutanée sur les activités quotidiennes
  • les relations personnelles et l’activité sexuelle du patient

L’échelle varie de 0 (aucune détérioration de la qualité de vie) à 30 (détérioration majeure de la qualité de vie) 

Evaluation du score DLQI


Score BSA

Le score BSA (19,20) (Body Surface Area: Surface corporelle atteinte)  est un score permettant de calculer le pourcentage de la surface corporelle atteinte par le psoriasis. Cette estimation est obtenue à partir de la paume du sujet (main posée à plat avec tous les doigts serrés, pouce inclus) représentant 1% de la surface corporelle totale.

Classification du score BSA:

  • Faible: < 2%
  • Modéré: 3-10%
  • Sévère: > 10% 

A lire aussi

Article

Evaluer la sévérité du psoriasis & Traitements disponibles

Article

Impact sur la qualité de vie
 

Article

Le Psoriasis en clair
 

1. Dubertret L. Le psoriasis : évolution et révolution. Médecine/Sciences 2006; 22 / 164-71.
2. International Federation of Psoriasis Associations – Our case. https://ifpa-pso.com/. Consulté le 22/10/2019.
3. Livre blanc de la SFD, Les défis de la dermatologie en France, 2018.
4. Global Report on Psoriasis. World Health Organization. 2016. Available at : http://apps.who.int/iris/bistream/10665/204417/1/9789241565189_eng.pdf.
5. About Psoriasis. National Psoriasis Foundation website. https://www.psoriasis.org/about-psoriasis. Consulté le 22/10/2019
6. International Federation of Psoriasis Associations. Psoriasis is a Serious Disease Deserving Global Attention. Available at: https://ifpa-pso.com/wp-content/uploads/2017/01/Brochure-Psoriasis-is-a-serious-disease-deserving-global-attention.pdf. Accessed July 2018.
7. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. Ann Dermatol Venereol. 2019 Jun - Jul;146(6-7):429-439
8. Ashcroft. Et al. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999;141:187. 
9. Manalo IF, Gilbert KE, Wu JJ. Time to Raise the Bar to psoriasis Area Severity Index 90 and 100. J Drugs Dermatol. 2015;14(10):1086-8
10. Nast A, Jacobs A, Rosumeck S et al. Methods Report: European S3-Guidelines on the systemic treatment of psoriasis vulgaris-upadte 2015-EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol.2015;29(12):e1-22.
11. Amatore F, Villani AP, Tauber M et al. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33(3):464-483.
12. Kamiya, K.; Kishimoto, M.; Sugai, J.; Komine, M.; Ohtsuki, M. Risk Factors for the Development of Psoriasis. Int. J. Mol. Sci. 2019, 20, 4347.
13. Psoriasis- Cours de dermatologie du CEDF /Annales de Dermatologie et de Vénéréologie (2012) 139. A112-A120
14. Psoriasis. In : Sugden M, Blundell R, eds. Clinical Dermatology. 4e é. Malden, MA. Blackwell Publishing, Inc.; 2008:54-70.
15. Baliwag J, Barnes DH, Johnstn A. Cytokines in psoriasis. Cytokine. 2015;73(2):342-350
16. Girolomoni G, Strohal R, Puig L, et al. The rôle of IL-23 and the IL-23/TH17 immune axis in the pathogenesis and treatment of psoriasis. JEADV. 2017;31:1616-1626
17. Duffy DL, Spelman LS, Martin NG. Psoriasis in Australian twins. J Am Acad Dermatol. 1993;29:428-434
18. Sweeney CM, Tobin AM, Kirby B. Innate immunity in the pathogenensis of psoriasis. Arch Dermatol Res. 2011;303(10):691-705.
19. Boehncke WH. Etiology and pathogenesis of psoriasis. Rheum Dis Clin N Am. 2015;41: 665-675.20.
20.Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overwview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850.
21. Puig L. The rôle of IL-23 in the treatment of psoriasis. Expert Rev Clin Immunol. 2017;13(6):525-34
22. Fotiadou C, LazaridouE, Sotiriou E et al. Targeting IL-23 in psoriasis: current perspectives. Psoriasis. 2018;8:1-5
23. Owczarczyk-Saczonek A, Czerwinska J, Placek W. The role of regulatory T cells and anti-inflammatory cytokines in psoriasis. Act Dermatol. 2018;27:17-23.
24. Bovenschen HJ, van de Kerkhof PC? Van Erp PE et al. Foxp3+ Regulatory T Cells of Psoriasis Patients Easily Differentiate into IL-17AProducing Cells and Are Found in Lestional Skin. J Invest Dermatol. 2011;231:1853-60.
25. Mrowietz U. et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Demratol Res 2011;303:1-10.
26. Finlay AY. Current severe psoriasis and the rule of Tens. Br J Dermatol 2005; 152:861-67
27. Walsh JA, et al. Product of the Physician Global Assessment and body surface area: A simple static measure of psoriasis severity in a longitudinal cohort. Journal of the American Academy of Dermatology, 2013;69(-):931-937
28.
https://dermato-info.fr/article/Le_psoriasis consulté le 20/11/2019 
29. Felman SR, Goffe B, Rice G. et al. The challenge of managing psoriasis: Unmet Medical Needs and Stakeholder Perspectives. Am Health Drug Benefits. 2016;9(9):504-513.
30. Mattei PL, Corey KC, Kimball AB. Psoriasis area severity index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J eur Acad Dermatol Venerol. 2014;28(3):333-7
31. Sumptom D, Kelly A, Tunnicliffe DJ et al. Patients’ perspectives and experience of psoriasis and psoriatic arthritis: a sytematic review and thematic synthetis of qualitative studies. Arthritis Care Res (Hoboken). 2019 Mar 30.
32. Dubertret L, Mrowietz U, Ranki A et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol. 2006;155(4):729-36.
33. Strober BE, vanderWalt, JM Armstong AW et al. Clinical goals and barriers to effective psoriasis care. Dermatol Ther(Heidelb). 2019;9:5-18.
34. Okubo Y, Tsuruta D, Tang AC et al. Analysis of treatment goal alignment between Japanese psoriasis patients and their paired treating physicians. JEADV. 2018;32:606-14.
35. Bewley A, Burrage DM, Ersser SJ et al. Identifying individual psychosocial and adherence support needs in patients with psoriasis: a multinational two-stage qualitative and quantitative study. J Eur Acad Dermatol Venerol. 2014;28:763-70.
36. Maul JT, Navarini AA, Sommer R. et al. Gender and age significantly determine patient needs and treatment goals in psoriasis – a lesson for practice. J Eur Acad Dermatol Venereol. 2019;33(4):700-8.
37. Radtke MA, Spehr C, Reich K et al. Treatment Satisfaction in Psoriasis: Development and Use of the PsoSat Patient Questionnaire in a Cross-Sectional Study. Dermatology. 2016;232:334-43.
38. Strober BE, Papp KA, Lebwohl M et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. 2016;75(1):77-82.
39. Feldman SR, Bushnemm DM, Klekotka PA et al. Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice. J Dermatol Treat. 2016;27(3):224-7.
40. Blome C, Gosau R, Radtke MA et al. Patient-relevant goals in psoriasis. Arch Dermatol Res. 2016;308:69-78.

FR-IMMD-190038 - 04/2020